Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRESS dexmedetomidine for refractory septic shock
2025-524122-18-00Phase 3Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexmedetomidine in septic shock (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Vital status at Day 30. Planned start Oct 2026; status: authorised.
02
Drugs
dexmedetomidine
03
Conditions
septic shock
Beyond the preview
Go deeper on 2025-524122-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524122-18-00.